Clinical trial
A Phase II Trial Evaluating Personalized Anal Squamous Cell Carcinoma Treatment Escalation Using Real-Time ctDNA Surveillance (PACER)
NCT07927998 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Evaluating Personalized Anal Squamous Cell Carcinoma Treatment Escalation Using Real-Time ctDNA Surveillance (PACER)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 4, 2026
- Completion date
- November 4, 2029
- Enrollment
- 25 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
anal cancer, anal carcinoma, anal squamous cell carcinoma
Arms
As registered; 1 arm.
-
Anal squamous cell carcinoma
Participants have pathologically confirmed anal squamous cell carcinoma
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Rate of ctDNA clearance at 12 weeks
To determine the rate of ctDNA clearance at 12-weeks (pre-Cycle 4) in ASCC participants with MRD after completion of definitive-intent chemoradiation, following treatment with retifanlimab.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Retifanlimab
- US 10577422; expires March 22, 2037; assignee Macrogenics Inc
Lead sponsor's other trials
Memorial Sloan Kettering Cancer Center, most recent start first.
+1,958 more trials See the organization page
Similar trials
Same condition (Anus Neoplasms) and phase, most recent start first.
+57 more trials See the condition page